Medidata’s Arnaub Chatterjee Named Fierce Healthcare and Fierce Medtech Rising Star
June 22, 2022— Fierce Healthcare and Fierce Medtech publications have named Arnaub Chatterjee as one of their 17 rising stars in health tech. Chatterjee is senior vice president of Acorn AI, the data sciences arm of Medidata, a Dassault Systèmes company.
According to Fierce, the list features “rising stars in the health tech world, including data scientists, engineers and designers who are looking to deliver on the beneficial potential of AI and new technologies in healthcare and can offer new ways forward for biopharma companies, drug developers, health system managers, primary care providers and academic researchers.”
At Medidata, Chatterjee focuses on data science-driven ways pharma and biotech can meaningfully de-risk clinical trials. This focus helps move the needle in drug development and trial operations while speeding up launch. In this capacity, he is overseeing novel capabilities at Medidata such as synthetic control arms, trial design, linking clinical and real world data to power evidence generation and commercial analytics.
He is a member of the faculties at both Harvard Medical School and Cornell University, where he teaches courses on health policy and healthcare data, respectively. He has been published for his work in data science in pharma in outlets such as Harvard Business Review and Nature. He is a governance committee member of the COVID-19 Research Database and a former board member of the World Economic Forum's Council on Biotechnology.
“There's this convergence between clinical trial and real-world data, which I think is the future of how data collection will look and how we may demystify why drugs aren't efficacious or safe outside of a trial environment,” Chatterjee said. “And though data science has evolved in a short period of time, it can still be difficult to get the clinical machinery working, and there's still some pretty fundamental problems.”
Chatterjee and his team strive to come up with ways where people can use the Medidata’s historical trial data set and its methods more iteratively in order to advance the entire process of trials, and take a data-science-first approach to development for the benefit of patients worldwide.
Senior Director, Corporate Communications & Affairs
External Communications Director